Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

A clinical study met its primary endpoint, with ASHA-defined hearing loss occurring in 24.0% of patients versus a prespecified historical benchmark of 56.4% (P=0.001). The 32.4-percentage-point reduction indicates statistically significant efficacy and is a materially positive development for the underlying therapy.